Clinical Trials
7 trialsNCT03233711 2026-05-13
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04929028 2026-05-13
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02314169 2026-05-12
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04444921 2026-05-04
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT02408861 2026-01-21
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed